UNSPSC 51112202: Cyclophosphamide/mannitol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AN100. This VA Drug Class (AN100) classifies this compound as belonging to the group ANTINEOPLASTICS, ALKYLATING AGENTS.

UNSPSC 51112202 Cyclophosphamide/mannitol is a Commodity code that covers a specific chemotherapy pharmaceutical product. State and local governments procure this agent primarily through state health and human services agencies and Medicaid programs that manage pharmacy benefit spending for eligible populations. The code reflects procurement of a branded or generic cyclophosphamide formulation combined with mannitol — a protective agent administered alongside cyclophosphamide to mitigate bladder toxicity — as part of cancer treatment protocols covered under state health plans. Purchasing occurs through direct pharmacy acquisitions, group purchasing organization (GPO) contracts, wholesale distribution channels, and increasingly through direct-to-manufacturer arrangements designed to improve cost management and supply chain efficiency within state pharmacy benefit programs.

The Texas Health and Human Services Commission (HHS) issued a Request for Information (RFI) on the Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program in April 2026, seeking vendor capabilities for establishing direct relationships between state pharmacy programs and pharmaceutical manufacturers outside traditional PBM and wholesaler arrangements. This RFI signals state interest in negotiated net pricing models and outcomes-based agreements for pharmacy products, including agents like cyclophosphamide/mannitol, to reduce acquisition costs and improve fulfillment efficiency. Beyond this single RFI, the source does not identify additional recent state or local solicitations under this code, suggesting limited recent activity in formal competitive procurement at the commodity-code level. Geographic concentration in Texas reflects current visibility, though chemotherapy pharmaceuticals are procured across multiple states through Medicaid and state employee health plans; formal RFPs or IFBs for this specific agent have not appeared in recent state and local notices included in the source material.